AstraZeneca
AstraZeneca plc (AZ) is a Swedish–British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.
Beyond's analysis on AstraZeneca
- — Approval of Merck's oral PCSK9 inhibitor LIPFENDRA and emerging oral competitors signal a high‑growth phase for the PCSK9 inhibitor market
- — Pascal Soriot rebounds from denied AstraZeneca-BMS merger rumors to reaffirm leadership amid market scrutiny
- — Oil prices fall over 5% as the US halts strikes on Iran, while AstraZeneca tops profit forecasts thanks to strong cancer-drug sales
- — GMP secures AstraZeneca’s Madrid office complex, bolstering its office portfolio amid rising corporate HQ interest in the city
Recent news mentioning AstraZeneca
- — AstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investment
- — AstraZeneca to invest over $1 billion in Massachusetts, boost workforce
- — SERD Market Set for Growth During the Forecast Period (2026-2036) as AstraZeneca's ETCAMAH Approval Accelerates Adoption of Oral SERDs | DelveInsight
- — Longo (AstraZeneca): "In Italia 66 milioni di investimenti e oltre 200 centri coinvolti"
- — Longo (AstraZeneca): "In Italia 66 milioni di investimenti e oltre 200 centri coinvolti"
- — AstraZeneca, in Italia programma investimenti in ricerca da 66,2 milioni in 3 anni
- — Anthropic warns of ‘existential risks to humanity’ from AI; AstraZeneca makes $2bn cancer drug tie-up – business live
- — AstraZeneca and Daiichi Sankyo’s Breast Cancer Drug Approved for NHS Use in England
- — AstraZeneca (AZN)’s Lung Drug Delivers the Good News its Pipeline Needed
- — AstraZeneca shares oversold after trial flops and merger talk, says UBS
- — AstraZeneca's news flow next year could sustain drugs group beyond 2030, says leading bank
- — Olema Pharmaceuticals Shares Fall 15.1% Following AstraZeneca SERENA-4 Trial Results